Search

Author/Creator Samakoglu, Selda

1. 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors. (10th December 2020)

Authors:
Aroldi, Francesca; Sacco, Joseph; Harrington, Kevin; Olsson-Brown, Anna; Nanclares, Pablo; Menezes, Lavita; Bommareddy, Praveen; Thomas, Suzanne; Kaufman, Howard; Samakoglu, Selda; Coffin, Robert; Middleton, Mark
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A256
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts. (9th November 2020)

Authors:
Middleton, Mark; Aroldi, Francesca; Sacco, Joseph; Milhem, Mohammed; Curti, Brendan; MBioeth, Ari VanderWalde; Baum, Scott; Samson, Adel; Pavlick, Anna; Chesney, Jason; Niu, Jiaxin; Rhodes, Terence; Bowles, Tawnya; Conry, Robert; Olsson-Brown, Anna; Laux, Douglas Earl; Kaufman, Howard; Bommareddy...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A257
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search